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during 1996. Six therapeutic categories were analyzed.
Statistical analyses utilizing multiple regression and anal-
ysis of covariance were performed. 
RESULTS: Significant associations (p  0.001) were
found between plan characteristics and cost of pharma-
ceuticals. Utilization differed (p  0.0001) among vari-
ous plan characteristics such as co-payment, mode of
payment, formulary status and pharmacy type after con-
trolling for average wholesale price and days supply. 
CONCLUSIONS: Results obtained in this study may be
helpful in understanding some of the factors associated
with cost of pharmaceuticals. For example, the inverse
relationship of pharmaceutical cost with eligible days
may be helpful in budgeting program costs while the
non-significant association of pharmaceutical cost with
number of members eligible suggests a lack of importance
of group size in negotiating pharmacy benefit contracts.
Differences in utilization among various co-payment levels
suggest the effectiveness of different co-payment levels in
promoting use of generic products. Lower utilization found
under capitation may be encouraging to those PBMs ac-
cepting a capitation method of reimbursement. Associa-
tion of closed formularies with higher utilization indicates
the importance of adjusting cost data for rebates before
evaluating formulary strategies. Finally, differences in utili-
zation between independent and chain pharmacies suggest
the importance of careful provider contract negotiation.
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Measures of adverse effect frequency and severity do not
accurately depict patients’ tolerance to an illness and/or a
treatment. The adverse effect frequency model is also a
weak predictor for tolerability and compliance. Additional
multidimensional variables are required to fully assess the
impact on quality of life which can be used as explanatory
variables to develop an index for bothersomeness to pre-
dict tolerability and hence compliance to therapy. 
OBJECTIVE: To develop a methodology for developing
an index of bothersomeness. 
METHODS: Data on bothersomeness were collected on
50 patients participating in a randomized, placebo-con-
trolled clinical trial. At baseline and final visits, patients
completed a questionnaire designed to capture the fre-
quency and bothersomeness of the impact of illness on
seven domains of quality of life. Regression methods
were used to test the response to bothersome scale for lin-
earity. Additive and predictive models were used to convert
the scale to a domain summary scores and hence a compos-
ite index for patient bothersomeness. Finally, multivariate
models (stepwise procedure) were used with clinical and
demographic variables as predictor and composite index
derived from additive and predictive methods as dependent
variables to estimate observed variance and model fit. 
RESULTS: An index scores for bothersomeness was esti-
mated using the additive and predictive methods using
data collected over time on 50 patients participating in a
clinical trial with the best model fit. 
CONCLUSION: The methodology used to calculate the
bothersome index can be used in other disease and treat-
ment modalities. The index scores may be used to better
describe patients’ tolerance, therefore improving the com-
munication between patient and physician when discussing
the treatment or illness impact on patients’ quality of life.
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OBJECTIVE: The purpose of this study was to conduct a
psychometric evaluation of the Patient Medication Ad-
herence Questionnaire (PMAQ), an HIV-specific instru-
ment designed to assess medication-taking behavior as
well as barriers and motivators affecting adherence. 
METHODS: The PMAQ was prospectively administered
to 410 patients in three studies: 1) a focus group of HIV
infected patients (n  67); 2) a cross-sectional observa-
tional cohort study (n  120); and 3) a clinical trail, with
evaluations at baseline, and weeks 8 and 16 (n  223).
The Multitrait/Multi-item Analysis Program-Revised was
used to evaluate reliability and validity for each of the five
hypothesized PMAQ dimensions: Remembering (REM),
Scheduling and Timing (SCH), Physical Effects (PE),
Knowledge and Attitudes (KNO), and Social Support (SS). 
RESULTS: Results consistent across the studies and
across multiple visits within the clinical trial are reported.
Cronbach’s alpha for four dimensions ranged between
0.43 to 0.73 and between 0.76 to 0.79 for the total score.
For the same dimensions, discriminant validity was suffi-
cient to suggest multitrait scaling even though a few
items within the dimensions produced weak (0.40)
item-scale correlations. To assess evidence of convergent
validity, the same dimensions had scale-scale correlations
0.42. The dimension that did not perform well across
these studies was KNO. Given its importance in earlier
research, this finding most probably reflects the heteroge-
neous nature of the items within this dimension. The cor-
relations between REM, SCH, and PE with missed doses
were moderate. SS was unrelated to missed doses. 
CONCLUSION: Even though the KNO dimension war-
rants further evaluation, the PMAQ generally demon-
strates adequate psychometric properties. It can be used
